• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

• 페이스북 공유
• 트위터 공유
• 

Personalized Depression Treatment

Traditional therapy and medication do not work for many people who are depressed. The individual approach to treatment could be the answer.

Cue is an intervention platform for digital devices that converts passively collected smartphone sensor data into personalized micro-interventions designed to improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to understand their predictors of feature and reveal distinct features that are able to change mood over time.

Predictors of Mood

Depression is among the leading causes of mental illness.1 However, only half of those suffering from the condition receive treatment1. In order to improve outcomes, doctors must be able to identify and treat patients who have the highest probability of responding to specific treatments.

A customized depression treatment is one way to do this. By using sensors on mobile phones, an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from the treatments they receive. With two grants awarded totaling more than $10 million, they will use these tools to identify the biological and behavioral factors that determine responses to antidepressant medications as well as psychotherapy.

The majority of research to the present has been focused on clinical and sociodemographic characteristics. These include demographics such as age, gender, and education, and clinical characteristics like symptom severity and comorbidities, as well as biological markers.

While many of these variables can be predicted from the data in medical records, only a few studies have employed longitudinal data to determine the factors that influence mood in people. Many studies do not take into consideration the fact that mood can vary significantly between individuals. It is therefore important to devise methods that allow for the analysis and measurement of personal differences between mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can identify different patterns of behavior and emotion that vary between individuals.

The team also developed an algorithm for machine learning to identify dynamic predictors of each person's depression mood. The algorithm combines these personal variations into a distinct "digital phenotype" for each participant.

This digital phenotype was found to be associated with CAT-DI scores, which is a psychometrically validated severity scale for symptom severity. However the correlation was not strong (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.

Predictors of symptoms

depression treatment history is among the world's leading causes of disability1 but is often not properly diagnosed and treated. In addition, a lack of effective treatments and stigmatization associated with depressive disorders prevent many from seeking treatment.

To facilitate personalized treatment to improve treatment, identifying the predictors of symptoms is important. The current methods for predicting symptoms rely heavily on clinical interviews, which are unreliable and only reveal a few characteristics that are associated with depression.

Machine learning can enhance the accuracy of the diagnosis and treatment of depression by combining continuous, digital behavioral phenotypes collected from smartphone sensors with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can be used to provide a wide range of unique actions and behaviors that are difficult to record through interviews and permit continuous and high-resolution measurements.

The study included University of California Los Angeles students who had mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical treatment according to the severity of their depression. Patients with a CAT DI score of 35 or 65 students were assigned online support by the help of a coach. Those with a score 75 patients were referred to in-person psychotherapy.

Participants were asked a series questions at the beginning of the study about their demographics and psychosocial traits. The questions included education, age, sex and gender and marital status, financial status, whether they were divorced or not, the frequency of suicidal thoughts, intent or attempts, as well as how often they drank. The CAT-DI was used to rate the severity of depression-related symptoms on a scale ranging from zero to 100. CAT-DI assessments were conducted each other week for participants that received online support, and every week for those who received in-person lithium treatment for depression.

Predictors of homeopathic treatment for depression Response

Research is focused on individualized depression treatment. Many studies are focused on finding predictors, which can aid clinicians in identifying the most effective drugs to treat each individual. Pharmacogenetics in particular is a method of identifying genetic variations that affect how the body's metabolism reacts to drugs. This lets doctors choose the medications that are likely to be the most effective for each patient, while minimizing time and effort spent on trial-and error treatments and avoid any negative side effects.

Another promising approach is building models for prediction using multiple data sources, combining the clinical information with neural imaging data. These models can be used to identify the most effective combination of variables predictive of a particular outcome, such as whether or not a drug will improve the mood and symptoms. These models can be used to determine the patient's response to a treatment they are currently receiving and help doctors maximize the effectiveness of their current therapy.

A new type of research utilizes machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to blend the effects of several variables and improve the accuracy of predictive. These models have proven to be useful in forecasting treatment outcomes, such as the response to antidepressants. These methods are becoming popular in psychiatry, and it is expected that they will become the norm for future clinical practice.

In addition to prediction models based on ML The study of the mechanisms behind depression is continuing. Recent research suggests that the disorder is connected with neural dysfunctions that affect specific circuits. This theory suggests that a individualized treatment for depression will depend on targeted therapies that restore normal functioning to these circuits.

One method to achieve this is to use internet-based interventions that can provide a more personalized and customized experience for patients. One study found that an internet-based program improved symptoms and improved quality life for MDD patients. A controlled, randomized study of a personalized treatment for depression found that a substantial percentage of patients experienced sustained improvement as well as fewer side consequences.

Predictors of side effects

A major challenge in personalized depression treatment is predicting which antidepressant medications will have very little or no side effects. Many patients take a trial-and-error approach, using several medications prescribed until they find one that is effective and tolerable. Pharmacogenetics offers a fascinating new way to take an efficient and targeted approach to choosing antidepressant medications.

There are many variables that can be used to determine the antidepressant to be prescribed, including genetic variations, phenotypes of patients such as gender or ethnicity, and comorbidities. However it is difficult to determine the most reliable and reliable predictors for a particular treatment is likely to require controlled, randomized trials with significantly larger numbers of participants than those that are typically part of clinical trials. This is due to the fact that the identification of interactions or moderators can be a lot more difficult in trials that consider a single episode of treatment options for depression per participant instead of multiple episodes of treatment over time.

Additionally, predicting a patient's response will likely require information on comorbidities, symptom profiles and the patient's subjective experience of tolerability and effectiveness. At present, only a handful of easily identifiable sociodemographic variables and clinical variables appear to be reliable in predicting the response to MDD. These include gender, age, race/ethnicity, SES, BMI and the presence of alexithymia.

Many challenges remain in the use of pharmacogenetics to treat depression. First is a thorough understanding of the underlying genetic mechanisms is required and a clear definition of what is a reliable indicator of treatment response. Additionally, ethical issues such as privacy and the ethical use of personal genetic information, should be considered with care. In the long term the use of pharmacogenetics could offer a chance to lessen the stigma that surrounds mental health treatment depression and to improve treatment outcomes for those struggling with depression. As with any psychiatric approach it is crucial to carefully consider and implement the plan. For now, it is best to offer patients various depression medications that work and encourage them to talk openly with their doctors.